Hikma Pharmaceuticals PLC (HIK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hikma Pharmaceuticals PLC (HIK) has a cash flow conversion efficiency ratio of 0.063x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX161.00 Million) by net assets (GBX2.55 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hikma Pharmaceuticals PLC - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Hikma Pharmaceuticals PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Hikma Pharmaceuticals PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hikma Pharmaceuticals PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FORCS Co.Ltd
KQ:189690
|
0.034x |
|
Magna Finance Tbk
JK:MGNA
|
-0.020x |
|
HARMONYCHAIN AS NK -05
F:7EW
|
N/A |
|
Tajiri Resources Corp
V:TAJ
|
-0.899x |
|
Seplat Petroleum Development Company PLC
LSE:SEPL
|
0.367x |
|
HOCHDORF HLDG AG
F:1Z3
|
N/A |
|
SEOJEON ELECTRIC MACHINERY Co.Ltd
KQ:189860
|
0.088x |
|
Podium Minerals Ltd
AU:POD
|
-0.007x |
Annual Cash Flow Conversion Efficiency for Hikma Pharmaceuticals PLC (2002–2024)
The table below shows the annual cash flow conversion efficiency of Hikma Pharmaceuticals PLC from 2002 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX2.32 Billion | GBX564.00 Million | 0.243x | -11.71% |
| 2023-12-31 | GBX2.21 Billion | GBX608.00 Million | 0.275x | +11.55% |
| 2022-12-31 | GBX2.15 Billion | GBX530.00 Million | 0.247x | -4.59% |
| 2021-12-31 | GBX2.47 Billion | GBX638.00 Million | 0.259x | +19.72% |
| 2020-12-31 | GBX2.15 Billion | GBX464.00 Million | 0.216x | -2.56% |
| 2019-12-31 | GBX2.13 Billion | GBX472.00 Million | 0.222x | -12.51% |
| 2018-12-31 | GBX1.70 Billion | GBX430.00 Million | 0.253x | -12.60% |
| 2017-12-31 | GBX1.53 Billion | GBX443.00 Million | 0.290x | +138.57% |
| 2016-12-31 | GBX2.41 Billion | GBX293.00 Million | 0.122x | -55.11% |
| 2015-12-31 | GBX1.35 Billion | GBX366.00 Million | 0.271x | -22.55% |
| 2014-12-31 | GBX1.22 Billion | GBX425.00 Million | 0.350x | +7.24% |
| 2013-12-31 | GBX1.03 Billion | GBX337.00 Million | 0.326x | +51.70% |
| 2012-12-31 | GBX847.85 Million | GBX182.16 Million | 0.215x | +67.18% |
| 2011-12-31 | GBX798.63 Million | GBX102.64 Million | 0.129x | -30.52% |
| 2010-12-31 | GBX750.30 Million | GBX138.79 Million | 0.185x | +19.78% |
| 2009-12-31 | GBX683.26 Million | GBX105.52 Million | 0.154x | +62.51% |
| 2008-12-31 | GBX609.00 Million | GBX57.87 Million | 0.095x | -6.41% |
| 2007-12-31 | GBX424.66 Million | GBX43.12 Million | 0.102x | +18.42% |
| 2006-12-31 | GBX349.80 Million | GBX29.99 Million | 0.086x | -24.65% |
| 2005-12-31 | GBX287.48 Million | GBX32.71 Million | 0.114x | -49.70% |
| 2004-12-31 | GBX145.18 Million | GBX32.84 Million | 0.226x | -25.43% |
| 2003-12-31 | GBX60.47 Million | GBX18.35 Million | 0.303x | +1.52% |
| 2002-12-31 | GBX48.03 Million | GBX14.35 Million | 0.299x | -- |
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and spe… Read more